Date: 2013-04-29
Type of information: Licensing agreement
Compound: STEP™ technology
Company: UvA Holding (The Netherlands) Batavia Bioservices (The Netherlands)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On April 29, 2013, Batavia Bioservices BV and UvA Holding BV have announced that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP™ technology developed by scientists at CellaGenics BV, an UvA Holding BV company. Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP™ technology, a plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more than 10-fold.
Financial terms: Financial details of the exclusive license agreement were not disclosed.
Latest news:
